PCSK9 inhibitors may improve outcomes but can we afford them?

06 Jul 2017 Dr. Duncan Hogg 39 Comments

Last I week I got my first query from a GP about prescribing Repatha (Evolocumab by Amgen), the monoclonal antibody that inhibits PCSK9, for a patient with atherosclerotic cardiovascular disease (ASCVD). This new group of medications are a fantastic piece of translational science, but in our financially pressured healthcare system are they a...